EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents

Silvia Borriello, Gabriele Roccuzzo iD, Paolo Dapavo, Nadia Sciamarrelli, Nicole Macagno, Francesco Leo iD, Pietro Quaglino, Simone Ribero iD, Luca Mastorino iD

Journal of Clinical Medicine · 25.10.2024 · 13 (21) · 6401

DOI: 10.3390/jcm13216401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.10.2024. Verfasst von Silvia Borriello und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis (PSO) involves about 1–3% of the population, and around 75% of women develop PSO before the age of 40. Official guidelines on the treatment of woman with anti-IL17 and anti-IL23 during this potential childbearing time are not currently available.

Objective

To investigate the effectiveness and safety of biologic treatments in women of childbearing age.

Methods

At the Dermatology Clinic of the University of Turin, Italy, 172 women aged 20–55 years underwent IL-17 and IL-23 inhibitor therapy for moderate-severe PSO and were followed up to 52 weeks in a real-life, retrospective, single-center study.

Results

Overall, 40% of patients achieved PASI 100 at week 16, and 72% at week 52. A similar trend was observed for PASI 90 and PASI < 3 with almost 80% and 90% of patients achieving the target at 52 weeks. As for PASI 100, a statistically significant difference (p = 0.004) was found at 16 weeks, with 23.84% of patients achieving PASI 100, with IL-17 and 15.70% with the IL-23 inhibitor. No statistically significant differences were found at 28 and 52 weeks. No statistically significant differences in PASIs at any time points were recorded across the different biologic agents. Forty-six patients discontinued treatment. The most reported side effects were headache, nausea, asthenia, injection site pain, and rhinitis.

Conclusions

This study showed that biologic drugs are effective and safe in women of childbearing age, with negligible side effects.

Schlagwörter

Stichwörter der Autor:innen

biologic therapybrodalumabixekizumabpsoriasissecukinumab

Autor:innen und Institutionen

  • Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

ORCID-Profile: Gabriele Roccuzzo, Francesco Leo, Simone Ribero, Luca Mastorino

Zitieren

APA

Borriello, S., Roccuzzo, G., Dapavo, P., Sciamarrelli, N., Macagno, N., Leo, F., Quaglino, P., Ribero, S., & Mastorino, L. (2024). Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents. Journal of Clinical Medicine, 13(21), 6401. https://doi.org/10.3390/jcm13216401

Vancouver

Borriello S, Roccuzzo G, Dapavo P, Sciamarrelli N, Macagno N, Leo F, et al. Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents. Journal of Clinical Medicine. 2024;13(21):6401. doi:10.3390/jcm13216401

BibTeX
@article{Borriello2024,
  author = {Borriello, Silvia and Roccuzzo, Gabriele and Dapavo, Paolo and Sciamarrelli, Nadia and Macagno, Nicole and Leo, Francesco and Quaglino, Pietro and Ribero, Simone and Mastorino, Luca},
  title = {Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {21},
  pages = {6401},
  doi = {10.3390/jcm13216401}
}
Kostenlos starten →